Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raed Alroughani

Showing results (121-130 of 223) with videos related to

Pageof 23
Sort By:
Neurology and Therapy|August 3, 2024
Practical Recommendations from the Gulf Region on the Therapeutic Use of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis: Impact of the Latest Real-World Evidence on Clinical PracticeBassem Yamout, Raed Alroughani, Jihad Inshasi, et al.
The Lancet. Child & Adolescent Health|March 28, 2024
Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registriesSifat Sharmin, Izanne Roos, Charles B Malpas, et al.
The Lancet. Neurology|February 21, 2026
Current evidence and knowledge gaps in family planning and pregnancy in myasthenia gravis, NMOSD, and MOGADDalia L Rotstein, Raed Alroughani, Georgina Arrambide, et al.
Neurology|March 11, 2014
Fingolimod after natalizumab and the risk of short-term relapseVilija G Jokubaitis, Vivien Li, Tomas Kalincik, et al.
Neurology|March 6, 2024
Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based StudyTim Spelman, Gabrielle Simoneau, Robert Hyde, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 21, 2018
Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosisMyintzu Min, Tim Spelman, Alessandra Lugaresi, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 27, 2024
Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBaseTim Spelman, Sara Eichau, Raed Alroughani, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 9, 2020
Prediction of on-treatment disability worsening in RRMS with the MAGNIMS scoreAmy Kunchok, Jeannette Lechner-Scott, Franco Granella, et al.
Neurology|May 29, 2026
Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term DisabilitySifat Sharmin, Izanne Roos, Pierre M Labauge, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|September 17, 2019
Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT studyLisanne J Balk, Danko Coric, Benjamin Knier, et al.
Pageof 23

Showing results (121-130 of 223) with videos related to

Sort By:
Pageof 23
Neurology and Therapy|August 3, 2024
Practical Recommendations from the Gulf Region on the Therapeutic Use of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis: Impact of the Latest Real-World Evidence on Clinical PracticeBassem Yamout, Raed Alroughani, Jihad Inshasi, et al.
The Lancet. Child & Adolescent Health|March 28, 2024
Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registriesSifat Sharmin, Izanne Roos, Charles B Malpas, et al.
The Lancet. Neurology|February 21, 2026
Current evidence and knowledge gaps in family planning and pregnancy in myasthenia gravis, NMOSD, and MOGADDalia L Rotstein, Raed Alroughani, Georgina Arrambide, et al.
Neurology|March 11, 2014
Fingolimod after natalizumab and the risk of short-term relapseVilija G Jokubaitis, Vivien Li, Tomas Kalincik, et al.
Neurology|March 6, 2024
Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based StudyTim Spelman, Gabrielle Simoneau, Robert Hyde, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 21, 2018
Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosisMyintzu Min, Tim Spelman, Alessandra Lugaresi, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 27, 2024
Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBaseTim Spelman, Sara Eichau, Raed Alroughani, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 9, 2020
Prediction of on-treatment disability worsening in RRMS with the MAGNIMS scoreAmy Kunchok, Jeannette Lechner-Scott, Franco Granella, et al.
Neurology|May 29, 2026
Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term DisabilitySifat Sharmin, Izanne Roos, Pierre M Labauge, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|September 17, 2019
Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT studyLisanne J Balk, Danko Coric, Benjamin Knier, et al.
Pageof 23